As shown in Figure 3(c), in the DFI survival analysis, high expression of MSH2 was all associated with poorer prognosis in ACC, CESC, KIRP, LIHC, LUSC, and PAAD. This evidence concerns the gene MSH2 and adrenal cortex carcinoma.